title: Application of HSVtk suicide gene to X-SCID gene therapy: ganciclovir treatment offsets gene corrected X-SCID B cells.
abstract: Recently, a serious adverse effect of uncontrolled clonal T cell proliferation due to insertional mutagenesis of retroviral vector was reported in X-SCID gene therapy clinical trial. To offset the side effect, we have incorporated a suicide gene into therapeutic retroviral vector for selective elimination of transduced cells. In this study, B-cell lines from two X-SCID patients were transduced with bicistronic retroviral vector carrying human gamma c chain cDNA and Herpes simplex virus thymidine kinase gene. After confirmation of functional reconstitution of the gamma c chain, the cells were treated with ganciclovir (GCV). The gamma c chain positive cells were eliminated under low concentration without cytotoxicity on untransduced cells and have not reappeared at least for 5 months. Furthermore, the gamma c chain transduced cells were still sensitive to GCV after five months. These results demonstrated the efficacy of the suicide gene therapy although further in vivo studies are required to assess feasibility of this approach in clinical trial.
authors.affiliation: Department of Pediatric Oncology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi 4-1, Aoba-ku, Sendai 980-8575, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Uchiyama
authors.forename: Satoru
authors.initials: S
authors.lastname: Kumaki
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Masafumi
authors.initials: M
authors.lastname: Onodera
authors.forename: Miki
authors.initials: M
authors.lastname: Sato
authors.forename: Wei
authors.initials: W
authors.lastname: Du
authors.forename: Yoji
authors.initials: Y
authors.lastname: Sasahara
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Tanaka
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sugamura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tsuchiya
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology*; D002460:Cell Line; D002461:Cell Line, Transformed; D049109:Cell Proliferation; D002470:Cell Survival; D018076:DNA, Complementary / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D005434:Flow Cytometry; D015774:Ganciclovir / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007376:Interleukin-2 / Q000378:metabolism; D053616:Janus Kinase 3; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000821:virology; D008957:Models, Genetic; D016296:Mutagenesis; D009154:Mutation; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D012190:Retroviridae; D016511:Severe Combined Immunodeficiency / Q000235:genetics* / Q000628:therapy*; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics*
chemical_list: D000998:Antiviral Agents; D018076:DNA, Complementary; D007376:Interleukin-2; D013937:Thymidine Kinase; D011505:Protein-Tyrosine Kinases; C507933:JAK3 protein, human; D053616:Janus Kinase 3; D015774:Ganciclovir